CLTCL1

Across TCGA pan-cancer cohorts, CLTCL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLTCL1 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CLTCL1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLTCL1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where CLTCL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.870	.012	19	view →
HNSC	OS	Quartile	IV	0.506	0.924	.011	8	view →
CCRCC	DFS	Tertile	III,IV	0.561	0.970	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLTCL1–LUAD (OS)

Open the LUAD breakdown →